Novelty Nobility
Latest round
- Series C
Last raised
- Nov 2024
Total raised
- $50M
Investors
- 21
About Novelty Nobility
, is a biotech company that works on the development and discovery of therapeutic antibodies, antibody-drug conjugates (ADCs), and ADC linker technologies to cure cancer and other medical conditions. In May 2022, Novelty Nobility Inc. The company is working on four drugs: NN2101, a monoclonal retinal disease therapeutic drug, NN3201, an antibody drug conjugate anti-cancer drug, NN2802, a chronic urticaria treatment drug, and NN3206, an ADC cancer drug with a pan-RAS inhibitor concept. Furthermore, the company has a PREXISE-D monoclonal antibody (mAbs) design and discovery platform that conducts human and mouse experiments to develop multi-purpose antibodies. PREXISETM-L is another patented, proprietary linker platform technology of the company that allows for the site-specific conjugation of various payloads to an intact antibody. Novelty Nobility Inc.
Who invested in Novelty Nobility
21 investors across 3 rounds
See all investors in Novelty Nobility
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Novelty Nobility
Who invested in Novelty Nobility?
Novelty Nobility has 21 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Novelty Nobility raised?
Novelty Nobility has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Novelty Nobility last raise money?
Novelty Nobility's most recent round on record is a Series C, in Nov 2024.
What does Novelty Nobility do?
, is a biotech company that works on the development and discovery of therapeutic antibodies, antibody-drug conjugates (ADCs), and ADC linker technologies to cure cancer and other medical conditions.
Where is Novelty Nobility headquartered?
Novelty Nobility is headquartered in Seongnam, South Korea.
Which VCs invest in companies like Novelty Nobility?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Novelty Nobility's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Novelty Nobility? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.